Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 4/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991126 | 0.94 | NR5A1 (0.52) | RARBCYP3A4TSHRMEN1USP2 | |
| SCHEMBL991315 | 0.93 | NR5A1 (0.51) | RARBCYP3A4TSHRMEN1USP2 | |
| SCHEMBL7276161 | 0.93 | NR5A1 (0.55) | RARBCYP3A4TSHRMEN1USP2 | |
| SCHEMBL7861362 | 0.93 | NR5A1 (0.55) | RARBCYP3A4TSHRMEN1USP2 | |
| SCHEMBL49992 | 0.90 | LTA4H (0.55) | CYP3A4TSHRSMN1; SMN2LTA4HNR5A1 | |
| SCHEMBL7928494 | 0.89 | LMNA (0.41) | RARBCYP3A4TSHRMEN1USP2 | |
| SCHEMBL27649786 | 0.88 | LTA4H (0.53) | CYP3A4TSHRSMN1; SMN2LTA4HNR5A1 | |
| SCHEMBL28106770 | 0.88 | LTA4H (0.53) | CYP3A4TSHRSMN1; SMN2LTA4HNR5A1 | |
| SCHEMBL10629620 | 0.88 | RARB (0.64) | RARBCYP3A4TSHRMEN1USP2 | |
| SCHEMBL10618259 | 0.87 | RARB (0.57) | RARBCYP3A4TSHRMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109862890-A | Purifying CENICRIVIROC and the purifying intermediate for being used to prepare CENICRIVIROC | 妥必徕疗治公司 | 2019-06-07 | — | — | CN | claimed |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| CN-109862890-A | Purifying CENICRIVIROC and the purifying intermediate for being used to prepare CENICRIVIROC | 妥必徕疗治公司 | 2019-06-07 | — | — | CN | disclosed |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3119401-A2 | CENICRIVIROC FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| WO-2015143367-A2 | CENICRIVIROC FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-9112081-B2 | Sealing film for solar cell and solar cell obtained by use of the sealing film | BRIDGESTONE CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-8741943-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1889839-B1 | Bicyclic compound, production and use as HIV inhibitors | TOBIRA THERAPEUTICS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-5472992-A | For printing inks, surface coatings, photoresists | CIBA-GEIGY CORPORATION (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0524419-B1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS (JP) | 1995-09-06 | — | — | EP | disclosed |
| US-5399770-A | Photoinitiator, preparation of printing plates, curing white paints | CIBA-GEIGY CORPORATION (US) | 1995-03-21 | — | — | US | disclosed |
| US-5391806-A | A storage stable chromogens as color-developing agent or stabilizers | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-02-21 | — | — | US | disclosed |
| US-5306688-A | Color-forming, electron donating compound and electron accepting compound; storage stability of uncolored portion | MITSUI TOATSU CHEMICALS, INC. (JP) | 1994-04-26 | — | — | US | disclosed |
| US-5270281-A | Chromogenic compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0534257-A1 | Salicylic acid derivatives, the process for preparing the same and the heat-sensitive recording materials comprising thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-03-31 | — | — | EP | disclosed |
| EP-0524419-A1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-27 | — | — | EP | disclosed |
| EP-0190444-B1 | OPTICAL-RECORDING MEDIUM | BASF Aktiengesellschaft (DE) | 1988-09-21 | — | — | EP | disclosed |
| EP-0190444-A1 | Optical-recording medium | BASF Aktiengesellschaft (DE) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | RARB 1673/4885CYP3A4 544/4885TSHR 2428/4885 |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | RARB 1676/4885CYP3A4 547/4885TSHR 2421/4885 |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | RARB 1676/4885CYP3A4 547/4885TSHR 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.